3D structures from the PDB for "HIV-1 protease" AND "BDBM8125"
(Proteins have >= 85% sequence identity and ligands are exact matches)

	Seq Identity	Jmol Display	PDB Title
4HLA	98%		CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH DARUNAVIR
4LL3	97%		STRUCTURE OF WILD-TYPE HIV PROTEASE IN COMPLEX WITH DARUNAVIR
6OPS	96%		HIV-1 PROTEASE NL4-3 WT IN COMPLEX WITH DARUNAVIR
6DGX	96%		CRYSTAL STRUCTURE OF HIV-1 PROTEASE NL4-3 WT IN COMPLEX WITH DARUNAVIR
6OOS	95%		HIV-1 PROTEASE NL4-3 L90M MUTANT IN COMPLEX WITH DARUNAVIR
6OOU	95%		CRYSTAL STRUCTURE OF HIV-1 PROTEASE NL4-3 L89V MUTANT IN COMPLEX WITH DARUNAVIR
6DH6	95%		CRYSTAL STRUCTURE OF HIV-1 PROTEASE NL4-3 I50V MUTANT IN COMPLEX WITH DARUNAVIR
6DH0	95%		CRYSTAL STRUCTURE OF HIV-1 PROTEASE NL4-3 I84V MUTANT IN COMPLEX WITH DARUNAVIR
6DH3	95%		CRYSTAL STRUCTURE OF HIV-1 PROTEASE NL4-3 V82I MUTANT IN COMPLEX WITH DARUNAVIR
6OOT	94%		HIV-1 PROTEASE NL4-3 L89V, L90M MUTANT IN COMPLEX WITH DARUNAVIR
6OPT	94%		HIV-1 PROTEASE NL4-3 V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
2IEN	93%		CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
3TKW	93%		CRYSTAL STRUCTURE OF HIV PROTEASE MODEL PRECURSOR/DARUNAVIR COMPLEX
2F80	92%		HIV-1 PROTEASE MUTANT D30N COMPLEXED WITH INHIBITOR TMC114
4Q1X	92%		MUTATIONS OUTSIDE THE ACTIVE SITE OF HIV-1 PROTEASE ALTER ENZYME STRUCTURE AND DYNAMIC ENSEMBLE OF THE ACTIVE SITE TO CONFER DRUG RESISTANCE
4Q1W	92%		MUTATIONS OUTSIDE THE ACTIVE SITE OF HIV-1 PROTEASE ALTER ENZYME STRUCTURE AND DYNAMIC ENSEMBLE OF THE ACTIVE SITE TO CONFER DRUG RESISTANCE
3PWM	92%		HIV-1 PROTEASE MUTANT L76V WITH DARUNAVIR
2IEO	92%		CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
3D20	92%		CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR DARUNAVIA
2IDW	92%		CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2HS1	92%		ULTRA-HIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE V32I MUTANT WITH TMC114 (DARUNAVIR) INHIBITOR
2HS2	92%		CRYSTAL STRUCTURE OF M46L MUTANT OF HIV-1 PROTEASE COMPLEXED WITH TMC114 (DARUNAVIR)
6OPU	92%		HIV-1 PROTEASE NL4-3 K45I, M46I, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
2F8G	92%		HIV-1 PROTEASE MUTANT I50V COMPLEXED WITH INHIBITOR TMC114
1T7I	92%		THE STRUCTURAL AND THERMODYNAMIC BASIS FOR THE BINDING OF TMC114, A NEXT-GENERATION HIV-1 PROTEASE INHIBITOR.
2F81	92%		HIV-1 PROTEASE MUTANT L90M COMPLEXED WITH INHIBITOR TMC114
3BVB	92%		CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND INHIBITOR DARUNAVIR
3D1Z	92%		CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR DARUNAVIR
1T3R	92%		HIV PROTEASE WILD-TYPE IN COMPLEX WITH TMC114 INHIBITOR
3JW2	92%		HIV-1 PROTEASE MUTANT G86S WITH DARUNAVIR
3CYW	92%		EFFECT OF FLAP MUTATIONS ON STRUCTURE OF HIV-1 PROTEASE AND INHIBITION BY SAQUINAVIR AND DARUNAVIR
3OY4	92%		CRYSTAL STRUCTURE OF HIV-1 L76V PROTEASE IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
5KQY	91%		PROTEASE E35D-DRV
4Q1Y	91%		MUTATIONS OUTSIDE THE ACTIVE SITE OF HIV-1 PROTEASE ALTER ENZYME STRUCTURE AND DYNAMIC ENSEMBLE OF THE ACTIVE SITE TO CONFER DRUG RESISTANCE
4DQB	90%		CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH DRV
3OXW	90%		CRYSTAL STRUCTURE OF HIV-1 I50V, A71V PROTEASE IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR
3S53	90%		HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P212121
3S54	90%		HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P21212
7MAS	90%		DRUG RESISTANT HIV-1 PROTEASE (L10F, M46I, I50V, F53L, L63P, G73S) IN COMPLEX WITH DRV
3LZS	90%		CRYSTAL STRUCTURE OF HIV-1 CRF01_AE PROTEASE IN COMPLEX WITH DARUNAVIR
5E5J	90%		JOINT X-RAY/NEUTRON STRUCTURE OF HIV-1 PROTEASE TRIPLE MUTANT (V32I, I47V,V82I) WITH DARUNAVIR AT PH 6.0
5E5K	90%		JOINT X-RAY/NEUTRON STRUCTURE OF HIV-1 PROTEASE TRIPLE MUTANT (V32I, I47V,V82I) WITH DARUNAVIR AT PH 4.3
3LZU	89%		CRYSTAL STRUCTURE OF A NELFINAVIR RESISTANT HIV-1 CRF01_AE PROTEASE VARIANT (N88S) IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
7MAQ	89%		DRUG RESISTANT HIV-1 PROTEASE (L10F, V32I, L33F, K45I, A71V, V82I, I84V) IN COMPLEX WITH DRV
4DQH	89%		CRYSTAL STRUCTURE OF (R14C/E65C) HIV-1 PROTEASE IN COMPLEX WITH DRV
3EKT	89%		CRYSTAL STRUCTURE OF THE INHIBITOR DARUNAVIR (DRV) IN COMPLEX WITH A MULTI-DRUG RESISTANT HIV-1 PROTEASE VARIANT (L10F/G48V/I54V/V64I/V82A) (REFER: FLAP+ IN CITATION.)
4DQF	88%		CRYSTAL STRUCTURE OF (G16A/L38A) HIV-1 PROTEASE IN COMPLEX WITH DRV
4DQC	88%		CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV
6OPV	88%		HIV-1 PROTEASE NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
4DQE	88%		CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV
7MAP	87%		DRUG RESISTANT HIV-1 PROTEASE (L10I, V32I, L33F, K45I, M46I, I50V, A71V, V82I, I84V) IN COMPLEX WITH DRV
6OPW	87%		HIV-1 PROTEASE NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
6OPX	87%		HIV-1 PROTEASE NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, L76V, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
5KR1	87%		PROTEASE PR5-DRV
7MAR	86%		DRUG RESISTANT HIV-1 PROTEASE (L10F, M46I, I47V, I50V, F53L, L63P, I72V, G73S, V82I, I85V) IN COMPLEX WITH DRV
6OPY	86%		HIV-1 PROTEASE NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, L76V, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
4NJT	86%		CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 PROTEASE IN COMPLEX WITH DARUNAVIR
6OPZ	85%		HIV-1 PROTEASE NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, I54L, A71V, L76V, V82F, I84V MUTANT IN COMPLEX WITH DARUNAVIR
3SO9	85%		DARUNAVIR IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT